RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Orphazyme A/S Stock

Orphazyme A/S ROE 2024

Orphazyme A/S ROE

-1.83

Ticker

ORPHA.CO

ISIN

DK0060910917

WKN

A2H7EV

In 2024, Orphazyme A/S's return on equity (ROE) was -1.83, a -313.67% increase from the 0.86 ROE in the previous year.

Orphazyme A/S Aktienanalyse

What does Orphazyme A/S do?

Orphazyme A/S is a Danish biopharmaceutical company specializing in the development of therapies for rare neurodegenerative diseases. They focus on researching amyloids, insoluble protein complexes found in various neurodegenerative diseases. Their business model involves developing and marketing therapeutic treatments for these rare neurodegenerative diseases. They specialize in four disease areas: Niemann-Pick disease type C (NPC), Gaucher disease, sporadic inclusion body myositis (sIBM), and amyotrophic lateral sclerosis (ALS). They concentrate on developing drugs that control lysosomal function and the breakdown of biocatalysts. Their advanced product, Arimoclomol, is currently being tested in a Phase 3 trial for the treatment of NPC disease. Orphazyme has collaborations with other companies and research institutions to advance their research and development efforts. These include a partnership with Sobi for the exclusive rights to market Arimoclomol in Europe and a collaboration with QIAGEN to develop biomarkers for diagnosing NPC disease. Overall, Orphazyme is a promising company focused on providing much-needed solutions for rare neurodegenerative diseases through their pipeline of therapies. They are well-positioned to become a leading player in the biopharmaceutical industry in the future. Orphazyme A/S ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Orphazyme A/S's Return on Equity (ROE)

Orphazyme A/S's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Orphazyme A/S's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Orphazyme A/S's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Orphazyme A/S’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Orphazyme A/S stock

What is the ROE (Return on Equity) of Orphazyme A/S this year?

The ROE of Orphazyme A/S this year is -1.83 undefined.

How has the Return on Equity (ROE) of Orphazyme A/S developed compared to the previous year?

The ROE of Orphazyme A/S has increased by -313.67% decreased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Orphazyme A/S?

A high ROE indicates that Orphazyme A/S generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Orphazyme A/S?

A low ROE can indicate that Orphazyme A/S is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Orphazyme A/S affect the company?

A change in ROE (Return on Equity) of Orphazyme A/S can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Orphazyme A/S?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Orphazyme A/S?

Some factors that can influence Orphazyme A/S's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Orphazyme A/S pay?

Over the past 12 months, Orphazyme A/S paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Orphazyme A/S is expected to pay a dividend of 0 DKK.

What is the dividend yield of Orphazyme A/S?

The current dividend yield of Orphazyme A/S is .

When does Orphazyme A/S pay dividends?

Orphazyme A/S pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Orphazyme A/S?

Orphazyme A/S paid dividends every year for the past 0 years.

What is the dividend of Orphazyme A/S?

For the upcoming 12 months, dividends amounting to 0 DKK are expected. This corresponds to a dividend yield of 0 %.

In which sector is Orphazyme A/S located?

Orphazyme A/S is assigned to the 'Health' sector.

Wann musste ich die Aktien von Orphazyme A/S kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Orphazyme A/S from 12/27/2024 amounting to 0 DKK, you needed to have the stock in your portfolio before the ex-date on 12/27/2024.

When did Orphazyme A/S pay the last dividend?

The last dividend was paid out on 12/27/2024.

What was the dividend of Orphazyme A/S in the year 2023?

In the year 2023, Orphazyme A/S distributed 0 DKK as dividends.

In which currency does Orphazyme A/S pay out the dividend?

The dividends of Orphazyme A/S are distributed in DKK.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Orphazyme A/S stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Orphazyme A/S

Our stock analysis for Orphazyme A/S Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Orphazyme A/S Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.